Komori
Presentation materials for financial results4547KISSEI PHARMACEUTICAL CO.,LTD.Pharmaceuticals

Supplementary Financial Results Materials for the Fiscal Year Ending March 2026

Although revenue increased in the fiscal year ended March 2026, the Company reported an operating loss and an ordinary loss due to a higher cost of sales ratio and increased R&D expenses. For the fiscal year ending March 2027, the Company expects revenue to decline but operating income and ordinary income to return to profitability, mainly due to a decline in R&D expenses following the prior-year increase.

Worth reading
71In focus
Scored from 4 of 6 sections
Direction
Mixed performance
Direction inferred from the company’s description.
Scale
97406
¥ million
Wording
Conditional
How definitive the wording is.

Contents of this document

Supplementary materials to the earnings reportFiscal year ending March 2026, full year9 items taken from the company’s own explanation
Financial Results Figures (The key points of this material are explained below)
Net Sales¥97,406 million+10.3%
Operating profit¥-2,927 million
Ordinary income¥-1,162 million
Net income¥13,779 million+15.2%
Selling, general and administrative expenses¥48,745 million
Gross Profit MarginGross profit margin: 47.0% (gross profit of ¥45,818 million ÷ revenue of ¥97,406 million; year-on-year change: Not disclosed)
Operating profit marginOperating loss margin: 3.0% (operating loss of ¥2,927 million ÷ revenue of ¥97,406 million; year-on-year change: Not disclosed)
Full-year earnings forecast
Net Sales
¥95,700 million
Operating profit
¥4,400 million
Ordinary income
¥6,000 million
Net income
¥14,500 million
What the company explained in this material
Breakdown of Factors Affecting the ChangeReasons cited by the Company for the change in the figures.
  • Increase in revenue from the Pharmaceuticals segment
  • Orders for projects related to the GIGA School Program in the Information Services segment
  • Increase in the Cost-of-Sales Ratio2.9 percentage points
  • Increase in Selling, General and Administrative ExpensesUp 27.3% year on year
  • Increase in R&D expensesUp 74.7% year on year, ¥22,521 million
  • Gain on sale of investment securities
New initiatives
  • Domestic launch of Iselty for uterine fibroids
  • Acquired exclusive development and marketing rights in Japan for 2 drugs for thyroid eye disease from Viridian Therapeutics
  • Granted Searchlight Pharma exclusive development and marketing rights in Canada for linzagolix
  • Granted development and marketing rights in Taiwan for olutasidenib
  • Opened the Boston Open Innovation Office
Key KPIsA metric the company considers important as a management benchmark.
  • Beova revenue¥21,547 million
    Year on year against the same period last year+15.5%
  • Tavneos revenue¥11,524 million
    Year on year against the same period last year+28.2%
  • Korsuva revenue¥8,072 million
    Year on year against the same period last year+52.8%
  • Tavalis revenue¥3,739 million
    Year on year against the same period last year+70.7%
  • Pirtobrutinib revenue¥3,996 million
    Year on year against the same period last year-10.0%
  • Darbepoetin alfa BS injection JCR revenue¥3,574 million
    Year on year against the same period last year-5.7%
  • Glubes and Glufast revenue¥2,645 million
    Year on year against the same period last year-17.6%
  • Epoetin alfa BS injection JCR revenue¥1,388 million
    Year on year against the same period last year-21.6%
  • Iselty revenue¥70 million
    Year on year against the same period last yearNew releases
Segment results
  • Pharmaceuticals Business
    Net Sales¥77,950 million
    Year on year against the same period last year+3.5%
  • Information Services Business
    Net Sales¥14,237 million
    Year on year against the same period last year+63.0%
  • Construction and Facility Maintenance
    Net Sales¥4,331 million
    Year on year against the same period last year+26.1%
  • Product sales business
    Net Sales¥886 million
    Year on year against the same period last year+2.9%
Number of employees
Number of Employees1,786 people
Change during the periodUp 8 people
Capital expenditures
¥5,699 million
Annual Dividend
Annual dividend per share¥160
Interim¥60
End of period¥100
Payout ratio
Payout ratio: 48.3% (total payout ratio: 86.0%)
Acquisition of treasury shares
Acquisition amount¥5,216 million
Number of shares acquired¥1,369 million
Share unitthousand shares
Contents of this document
ItemDetails
Document typeSupplementary materials to the earnings report
Fiscal Period CoveredFiscal year ending March 2026, full year
Net Sales¥97,406 million (YoY +10.3%)
Operating profit¥-2,927 million
Ordinary income¥-1,162 million
Net income¥13,779 million (YoY +15.2%)
Gross Profit MarginGross profit margin: 47.0% (gross profit of ¥45,818 million ÷ revenue of ¥97,406 million; year-on-year change: Not disclosed)
Operating profit marginOperating loss margin: 3.0% (operating loss of ¥2,927 million ÷ revenue of ¥97,406 million; year-on-year change: Not disclosed)
Selling, general and administrative expenses¥48,745 million
Full-year earnings forecastNet Sales ¥95,700 million / Operating profit ¥4,400 million / Ordinary income ¥6,000 million / Net income ¥14,500 million
Segment resultsSegment Pharmaceuticals Business / Net Sales ¥77,950 million / Year on year against the same period last year 3.5, Segment Information Services Business / Net Sales ¥14,237 million / Year on year against the same period last year 63, Segment Construction and Facility Maintenance / Net Sales ¥4,331 million / Year on year against the same period last year 26.1, Segment Product sales business / Net Sales ¥886 million / Year on year against the same period last year 2.9
Breakdown of Factors Affecting the ChangeFactors Increase in revenue from the Pharmaceuticals segment / Amount Not disclosed, Factors Orders for projects related to the GIGA School Program in the Information Services segment / Amount Not disclosed, Factors Increase in the Cost-of-Sales Ratio / Amount 2.9 percentage points, Factors Increase in Selling, General and Administrative Expenses / Amount Up 27.3% year on year, Factors Increase in R&D expenses / Amount Up 74.7% year on year, ¥22,521 million, Factors Gain on sale of investment securities / Amount Not disclosed
Key KPIsIndicator name Beova revenue / Value ¥21,547 million / Year on year against the same period last year ¥15.5 million, Indicator name Tavneos revenue / Value ¥11,524 million / Year on year against the same period last year ¥28.2 million, Indicator name Korsuva revenue / Value ¥8,072 million / Year on year against the same period last year ¥52.8 million, Indicator name Tavalis revenue / Value ¥3,739 million / Year on year against the same period last year ¥70.7 million, Indicator name Pirtobrutinib revenue / Value ¥3,996 million / Year on year against the same period last year ¥-10 million, Indicator name Darbepoetin alfa BS injection JCR revenue / Value ¥3,574 million / Year on year against the same period last year ¥-5.7 million, Indicator name Glubes and Glufast revenue / Value ¥2,645 million / Year on year against the same period last year ¥-17.6 million, Indicator name Epoetin alfa BS injection JCR revenue / Value ¥1,388 million / Year on year against the same period last year ¥-21.6 million, Indicator name Iselty revenue / Value ¥70 million / Year on year against the same period last year New releases
Number of employeesNumber of Employees 1,786 people / Change during the period Up 8 people
Annual DividendAnnual dividend per share ¥160 / Interim ¥60 / End of period ¥100
Payout ratioPayout ratio: 48.3% (total payout ratio: 86.0%)
Acquisition of treasury sharesAcquisition amount ¥5,216 million / Number of shares acquired ¥1,369 million / Share unit thousand shares / Period Not disclosed
Capital expenditures¥5,699 million
New initiativesDomestic launch of Iselty for uterine fibroids, Acquired exclusive development and marketing rights in Japan for 2 drugs for thyroid eye disease from Viridian Therapeutics, Granted Searchlight Pharma exclusive development and marketing rights in Canada for linzagolix, Granted development and marketing rights in Taiwan for olutasidenib, Opened the Boston Open Innovation Office
Items this document does not state (12)
Results for the three months of the current quarterProgress against full-year forecastSelf-assessment against the planUnit price and quantity metricsNumber of stores and locationsAssumptions Underlying the Business OutlookRisk amount incorporated into the outlookMedium-term management plan targetsFinancial targetsOrders received and order backlogMarket Size / ShareKey points of the Q&A

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

Revenue increased in the fiscal year ended March 2026, driven by growth in pharmaceutical sales, including Beova, Tavneos, Korsuva and Tavalis, as well as orders for projects related to the GIGA School Program. On the other hand, the Company reported an operating loss and an ordinary loss due to a higher cost of sales ratio, resulting mainly from lower technical fee revenue, and increased selling, general and administrative expenses, primarily R&D expenses related to technology introductions. Net income attributable to owners of the parent increased due to extraordinary income, including gains on sales of investment securities.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Supplementary Financial Results Materials for the Fiscal Year Ending March 2026 | KISSEI PHARMACEUTICAL CO.,LTD. (4547) timely disclosure | Komori